In two cases of gynecological cancer harboring the same mutation in PIK3CA and PTEN, the drug response profiles were completely distinct, showing that, used together, PDTO and NGS/WES could better select patients who could benefit from these therapies [195]. This evidence concerns the gene PIK3CA and female reproductive organ cancer.